RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > Regulatory Update

Regulatory Update

Posted 01 July 2010

The US Food and Drug Administration (FDA) recently announced the availability of Guidance for Industry: Bioequivalence Recommendations for Specific Products.' This guidance describes a new process for making available recommendations on how to design product-specific bioequivalence (BE) studies to support Abbreviated New Drug Applications (ANDAs). Applicants planning to carry out such studies in support of their ANDAs can access BE study guidance on the FDA website. FDA believes that making this information available on the Internet will streamline the guidance process and will provide a meaningful opportunity for the public to consider and comment on product-specific BE study recommendations.


© 2022 Regulatory Affairs Professionals Society.